BioMedNewsBreaks Archive - Page 4 of 277

ThursdayJun 25, 2026 9:20 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it is featured in a BioMedWire editorial examining the growing market opportunity for next-generation DNA Damage Response ("DDR") inhibitors. The editorial, titled "Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market," highlights the continued expansion of DDR-targeted therapies beyond PARP inhibitors as the global oncology, diagnostics and precision medicine markets continue to grow. The editorial highlights Onco-Innovations' lead candidate, ONC010™, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple repair pathways. The…

WednesdayJun 24, 2026 1:53 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed the company’s efforts to move beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. The publication reads, “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments… At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise,…

WednesdayJun 24, 2026 1:12 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development…

WednesdayJun 24, 2026 9:50 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety…

WednesdayJun 24, 2026 9:40 am

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning. Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company…

WednesdayJun 24, 2026 9:20 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced a services agreement with Nanosoft Polymers to support development of ONC010, the company’s lead nanoparticle-formulated PNKP inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support and technology transfer services for Onco’s proprietary PEO-PBCL polymer platform as the program advances through IND-enabling development and preparation for future clinical studies. The collaboration is intended to strengthen the manufacturing and formulation foundation of ONC010 by establishing scalable polymer production processes, enhancing analytical methods and…

WednesdayJun 24, 2026 9:00 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline

VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of infrastructure needed to advance future development activities. VERAXA said the expansion aligns with efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC…

TuesdayJun 23, 2026 9:47 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a BioMedWire editorial examining the growing market for DNA Damage Response inhibitor (“DDRi”) therapies and the next generation of cancer treatments targeting DNA repair pathways. The article highlights the company’s lead candidate, ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a key DNA repair enzyme involved in multiple repair mechanisms, positioning Onco-Innovations among emerging developers seeking to advance new synthetic lethality approaches in precision oncology. To view the full press release, visit https://ibn.fm/3dhdy About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment,…

TuesdayJun 23, 2026 9:24 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (“MS”), a disease affecting more than 2.9 million people worldwide. The article highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS, and notes that the program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease. To view the full press release, visit https://ibn.fm/KdvrI About Quantum BioPharma Ltd. Quantum is…

MondayJun 22, 2026 1:09 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) was featured in a BioMedWire editorial examining the rapidly expanding DNA Damage Response inhibitor market, where new drug classes are emerging beyond PARP inhibitors. The company is advancing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to the editorial, Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology and is positioning itself as an early leader in a novel class of cancer therapeutics. Onco-Innovations highlighted preclinical data showing ONC010 more than doubled…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Eyes Opportunity Through AI and Pharmaceutical Automation

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search